Journal
CANCER
Volume 122, Issue 18, Pages 2787-2798Publisher
WILEY
DOI: 10.1002/cncr.30094
Keywords
clinical trials; endometrial cancer; genomics; Lynch syndrome; molecular classification; obesity and lifestyle factors; DNA polymerase epsilon catalytic subunit (POLE) mutations; targeted therapy; The Cancer Genome Atlas (TCGA)
Categories
Funding
- Canadian Institute of Health Research
- Canadian Cancer Society
- British Columbia Cancer Foundation
Ask authors/readers for more resources
Worldwide, the incidence of endometrial carcinoma (EC) is rapidly increasing, and the highest disease burden is reported in North America and Western Europe. Although the prognosis remains good for patients with are diagnosed with early stage EC, for those with recurrent or metastatic disease, the options are few, and the median overall survival is short. It is imperative to gain a greater understanding of all aspects of EC, limit its effect on scarce health care resources and, more importantly, prevent this cancer from significantly impacting future generations of women. An exciting new era of endometrial cancer research and clinical management has begun that incorporates biologically and clinically relevant genomic and clinicopathologic parameters. Continued collaborative research efforts and funding are essential if we are to advance our understanding of this disease and improve clinical outcomes. Cancer 2016. (c) 2016 American Cancer Society. Cancer 2016;122:2787-2798. (c) 2016 American Cancer Society
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available